Cargando…

Undetectable RAS-Mutant Clones in Plasma: Possible Implication for Anti-EGFR Therapy and Prognosis in Patients With RAS-Mutant Metastatic Colorectal Cancer

PURPOSE: Combining cetuximab with chemotherapy provides clinical benefit to 60% of the patients with RAS wild-type (RAS-wt) metastatic colorectal cancer (mCRC). This pilot study investigated the efficacy of cetuximab-based chemotherapy in a sample of patients (40%) with RAS mutation (RAS-mt) in thei...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bouchahda, Mohamed, Saffroy, Raphael, Karaboué, Abdoulaye, Hamelin, Jocelyne, Innominato, Pasquale, Saliba, Faouzi, Lévi, Francis, Bosselut, Nelly, Lemoine, Antoinette
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Clinical Oncology 2020
Materias:	Original Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7529530/ https://www.ncbi.nlm.nih.gov/pubmed/33015528 http://dx.doi.org/10.1200/PO.19.00400

Ejemplares similares

Impact of country of birth on genetic testing of metastatic lung adenocarcinomas in France: African women exhibit a mutational spectrum more similar to Asians than to Caucasians
por: Saffroy, Raphael, et al.
Publicado: (2017)

Monitoring of RAS mutant clones in plasma of patients with RAS mutant metastatic colorectal cancer
por: Fernández Montes, A., et al.
Publicado: (2022)

Transient Disappearance of RAS Mutant Clones in Plasma: A Counterintuitive Clinical Use of EGFR Inhibitors in RAS Mutant Metastatic Colorectal Cancer
por: Raimondi, Cristina, et al.
Publicado: (2019)

Mitochondrial Roles and Cytoprotection in Chronic Liver Injury
por: Degli Esposti, Davide, et al.
Publicado: (2012)

Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228)
por: Lévi, Francis, et al.
Publicado: (2017)

Chronological occurrence of PI3KCA mutations in breast cancer liver metastases after repeat partial liver resection
por: Ruiz, Aldrick, et al.
Publicado: (2019)

Time-Dependent Efficacy of Checkpoint Inhibitor Nivolumab: Results from a Pilot Study in Patients with Metastatic Non-Small-Cell Lung Cancer
por: Karaboué, Abdoulaye, et al.
Publicado: (2022)

The effects of mutant Ras proteins on the cell signalome
por: Takács, Tamás, et al.
Publicado: (2020)

Inhibition of mutant RAS-RAF interaction by mimicking structural and dynamic properties of phosphorylated RAS
por: Ilter, Metehan, et al.
Publicado: (2022)

Direct targeting of oncogenic RAS mutants with a tumor-specific cytosol-penetrating antibody inhibits RAS mutant–driven tumor growth
por: Shin, Seung-Min, et al.
Publicado: (2020)

Identification of RAS mutant biomarkers for EGFR inhibitor sensitivity using a systems biochemical approach
por: McFall, Thomas, et al.
Publicado: (2021)

Argonaute 2 modulates EGFR–RAS signaling to promote mutant HRAS and NRAS-driven malignancies
por: Siebenaler, Ronald F, et al.
Publicado: (2022)

Detection of Mutant RAS Subpopulations in Colorectal Cancer Patients
por: Banda, Malathi
Publicado: (2015)

Selective and noncovalent targeting of RAS mutants for inhibition and degradation
por: Teng, Kai Wen, et al.
Publicado: (2021)

Genomic Landscapes and Hallmarks of Mutant RAS in Human Cancers
por: Scharpf, Robert B., et al.
Publicado: (2022)

Mutant K-Ras in Pancreatic Cancer: An Insight on the Role of Wild-Type N-Ras and K-Ras-Dependent Cell Cycle Regulation
por: Ferguson, Robert, et al.
Publicado: (2023)

Sex‐dependent least toxic timing of irinotecan combined with chronomodulated chemotherapy for metastatic colorectal cancer: Randomized multicenter EORTC 05011 trial
por: Innominato, Pasquale F., et al.
Publicado: (2020)

Efficacy and safety of chronomodulated irinotecan, oxaliplatin, 5‐fluorouracil and leucovorin combination as first‐ or second‐line treatment against metastatic colorectal cancer: Results from the International EORTC 05011 Trial
por: Innominato, Pasquale F., et al.
Publicado: (2020)

Disruption of the Interaction of RAS with PI 3-Kinase Induces Regression of EGFR-Mutant-Driven Lung Cancer
por: Murillo, Miguel M., et al.
Publicado: (2018)

Restoration of mutant K-Ras repressed miR-199b inhibits K-Ras mutant non-small cell lung cancer progression
por: Jin, Hua, et al.
Publicado: (2019)

Comparative Analysis of Radiosensitizers for K-RAS Mutant Rectal Cancers
por: Kleiman, Laura B., et al.
Publicado: (2013)

Targeting RAS mutants in malignancies: successes, failures, and reasons for hope
por: Yang, Hang, et al.
Publicado: (2022)

Injury prevents Ras mutant cell expansion in mosaic skin
por: Gallini, Sara, et al.
Publicado: (2023)

Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP
por: McFall, Thomas, et al.
Publicado: (2022)

RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers
por: Nichols, Robert J., et al.
Publicado: (2018)

Impact of circulating tumor DNA mutant allele fraction on prognosis in RAS‐mutant metastatic colorectal cancer
por: Elez, Elena, et al.
Publicado: (2019)

An unexpected new role of mutant Ras: perturbation of human embryonic development
por: Kratz, Christian P., et al.
Publicado: (2007)

Interactions Between Wildtype and Mutant Ras Genes in Lung and Skin Carcinogenesis
por: To, Minh D., et al.
Publicado: (2012)

Cytotoxicity of Simvastatin to Pancreatic Adenocarcinoma Cells Containing Mutant ras Gene
por: Ura, Hitoshi, et al.
Publicado: (1994)

Oncogenic mutant RAS signaling activity is rescaled by the ERK/MAPK pathway
por: Gillies, Taryn E, et al.
Publicado: (2020)

Clinical Translation of Combined MAPK and Autophagy Inhibition in RAS Mutant Cancer
por: Lee, Jennifer J., et al.
Publicado: (2021)

The levels of mutant K-RAS and mutant N-RAS are rapidly reduced in a Beclin1 / ATG5 -dependent fashion by the irreversible ERBB1/2/4 inhibitor neratinib
por: Booth, Laurence, et al.
Publicado: (2017)

Detection of mutant K-ras DNA in plasma or serum of patients with colorectal cancer.
por: Kopreski, M. S., et al.
Publicado: (1997)

Expression, purification, crystallization and X-ray data collection for RAS and its mutants
por: Johnson, Christian W., et al.
Publicado: (2015)

Combined targeting of MEK and the glucocorticoid receptor for the treatment of RAS-mutant multiple myeloma
por: Sriskandarajah, Priya, et al.
Publicado: (2020)

Structure-based inhibitor design of mutant RAS proteins—a paradigm shift
por: Nyíri, Kinga, et al.
Publicado: (2020)

Genomic landscape and survival analysis of ctDNA “neo-RAS wild-type” patients with originally RAS mutant metastatic colorectal cancer
por: Nicolazzo, Chiara, et al.
Publicado: (2023)

Phosphorylated EGFR Dimers Are Not Sufficient to Activate Ras
por: Liang, Samantha I., et al.
Publicado: (2018)

Mutant N-RAS Induces Erythroid Lineage Dysplasia in Human CD34(+) Cells
por: Darley, Richard L., et al.
Publicado: (1997)

Metformin inhibits urothelial tumorigenesis in the UPII-mutant Ha-ras transgenic mouse model
por: Liu, Zhongbo, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_65s5sjpqbe5skdb3f5o2ac20jk